Comparison of the effect of roxadustat and human erythropoietin injection in hemodialysis patients
Objective To analyze the effect of roxadustat and human erythropoietin injection on hemodialysis patients.Methods Data of the patients who received hemodialysis treatment in Emergency General Hospital from December 2021 to December 2023 were selected and the patients were divided into the test group(treated with oral roxadustat)and the control group(treated with human erythropoietin subcutaneous injection)according to the treatment schemes.The levels of hemoglobin(HB),hematocrit(HCT),erythropoietin(EPO),transferrin saturation(TSAT),unsaturated iron binding capacity(UIBC),ferritin(SF),fibroblast growth factor-23(FGF-23),NADPH oxidase 2(NOX2),advanced protein oxidation product(AOPP),P-selectin(CD62P),C-reactive protein(CRP),interleukin-1β(IL-1β),interleukin-6(IL-6),claudin-1(CLDN-1)and the incidence of adverse reactions were compared between the two groups.Results A total of 80 patients were included,with 40 patients in each group.After treatment,the levels of Hb,HCT,SF,TSAT and CLDN-1 in the test group were higher than those in the control group,while the levels of EPO,UIBC,FGF-23,AOPP,NOX2,CD62P,CRP,IL-1 β and IL-6 in the test group were lower than those in the control group(P＜0.05).The incidence of adverse reactions in the test group was lower than that in the control group(P＜0.05).Conclusion Compared with human erythropoietin injection,roxadustat can significantly correct the anemia state of hemodialysis patients,regulate the iron metabolism,improve the inflammation and the oxidative stress response,and has high effectiveness and safety.
RoxadustatRecombinant human erythropoietin injectionHemodialysisHemoglobinIron metabolismAnemia
NETL
NSTL
万方数据
